1 |
Gähwiler EKN, Motta SE, Martin M, Nugraha B, Hoerstrup SP, Emmert MY. Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering. Front Cell Dev Biol 2021;9:639699. [PMID: 34262897 DOI: 10.3389/fcell.2021.639699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
2 |
Lujan H, Romer E, Salisbury R, Hussain S, Sayes C. Determining the Biological Mechanisms of Action for Environmental Exposures: Applying CRISPR/Cas9 to Toxicological Assessments. Toxicol Sci 2020;175:5-18. [PMID: 32105327 DOI: 10.1093/toxsci/kfaa028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
3 |
Schmidt C, Schindele P, Puchta H. From gene editing to genome engineering: restructuring plant chromosomes via CRISPR/Cas. aBIOTECH 2020;1:21-31. [PMID: 36305002 DOI: 10.1007/s42994-019-00002-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
|
4 |
Vermersch E, Jouve C, Hulot J. CRISPR/Cas9 gene-editing strategies in cardiovascular cells. Cardiovascular Research 2020;116:894-907. [DOI: 10.1093/cvr/cvz250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
5 |
Stephens CJ, Lauron EJ, Kashentseva E, Lu ZH, Yokoyama WM, Curiel DT. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. J Control Release 2019;298:128-41. [PMID: 30771412 DOI: 10.1016/j.jconrel.2019.02.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
|
6 |
Sakuma T, Yamamoto T. Acceleration of cancer science with genome editing and related technologies. Cancer Sci 2018;109:3679-85. [PMID: 30315615 DOI: 10.1111/cas.13832] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|